Navigate Fool.com
Will OMED beat
the market?
Community Rating: 2 Stars: Unattractive

25.99 0.00 (0.00%)

Quote as of

Extended Hours: $25.99 $0.00 (0.00%)
Quote as of (NASDAQ)

company name or ticker

Recent Quotes

1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $25.68
Previous Close $25.99
Daily Range $24.00 - $26.29
52-Week Range $12.07 - $42.34
Market Cap $766.2M
P/E Ratio -12.95
Dividend (Yield) $0.00 (0.0%)
Volume 218,329
Average Daily Volume 206,586
Current FY EPS -$0.49

How do you think OMED
will perform against the market?

Top OMED Bull/Bear Pitches


There are no pitches that meet the Top Bull criteria. Explain

If this upsets you, start recommending pitches here!


There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches here!

News & Commentary Rss Feed

The 5 Most Hated Biotechs: Myriad, Sarepta, OncoMed, VIVUS, and MannKind

The five biotechs with the largest number of shares sold short as a percentage of float.

What You Ought To Know About Celgene's Deal-Making Magic

Celgene's investment team has made a string of savvy investments in early stage biotech companies.

5 States Where Pancreatic Cancer Prevalence Is the Highest

Pancreatic cancer has the lowest five-year survival rate and is the most prevalent in these five states. Here are the existing and developing therapies you need to have your eyes on.

This Week in Biotech: Clinical Trials and Tribulations

The J.P. Morgan Healthcare Conference led to the release of five important clinical updates this week.

Why OncoMed Pharmaceuticals, Inc. Shares Temporarily Spiked Higher

OncoMed Pharmaceuticals shares jump after the company releases early-stage data on two advanced pancreatic cancer drugs. Should investors be just as excited?

How Researchers Are Waging War on the Most Lethal Type of Cancer

Pancreatic cancer is the 12th most diagnosed cancer, but it is by far the most lethal. Find out how treatments are evolving and how patients and investors may soon benefit from these discoveries.

"Star Trek" Becomes Reality With These 3 Revolutionary Cancer-Fighting Methods

The next-generation of cancer-fighting agents could be right around the corner.

Is Celgene Really Overvalued?

High-profile analysts are worrying over Celgene's share price, but a strong pipeline suggests a bright future for the company.

Why LSI, AerCap Holdings, and OncoMed Pharmaceuticals Are Today's 3 Best Stocks

The S&P 500 puts its four-day losing streak in the rearview mirror following strong economic data, but LSI, AerCap, and OncoMed Pharmaceuticals stole the show with gains of more than 20%!

Novartis Strengthens in Oncology With Multiple Myeloma

Novartis' strong R&D proves itself in the face of rivals' acquisitions and restructuring

See More OMED News...




ONCOMED PHARMACEUTICALS INC Website: http://www.oncomed.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks